REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
12/15/2025
Back to search
Official data from USPTO
9 ML STERILE OPHTHALMIC DROPS PILOCARPINE HCI / PHENYLEPHRINE HCI / PHENIRAMINE / KETOROLAC 0.302% / 0.624% / 0.0772% / 0.01% EYEFOCUS BY OSRX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
12/16/2025
Trademark type
Combined
Nice classes
5
Filing date
05/07/2020
Registration date
12/15/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/15/2020
Last transaction
12/16/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
02/26/2020
First use in commerce
02/26/2020
Drawing code
3
Owner type
03
Owner location
Missoula, MT
Examiner
GOLD, BARBARA
Law office
L60
Current location
TMEG LAW OFFICE 106
Mark description
The mark consists of two rectangles stacked vertically with the stylized wording "9 ML STERILE OPHTHALMIC DROPS" above "PILOCARPINE HCI / PHENYLEPHRINE HCI /" above "PHENIRAMINE / KETOROLAC" above "0.302% / 0.624% / 0.0772% / 0.01%" in the top rectangle, and the stylized wording "EYEFOCUS" above "BY OSRX" in the bottom rectangle, with the fanciful design of a human eye representing the "O" of "FOCUS".
Holders and representatives
Holders
OSRX, Inc.
Representatives
Brendan J. Hughes Cooley LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparationsophthalmic preparations containing Philocarpine; pharmaceutical preparations containing Philocarpine for the treatment of ophthalmic diseases and conditions; pharmaceutical preparations containing Philocarpine for the treatment of presbyopia with eye drops
Publications
History of USPTO decisions and trademark events.
30 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/21/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/21/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/21/2025
WOAG
WITHDRAWAL OF ATTORNEY GRANTED
03/10/2025
WOAR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED
03/10/2025
PRA7
REGISTERED - SEC. 7 REQUEST ABANDONED
03/05/2021
PRAN
POST REGISTRATION ACTION MAILED NO RESPONSE REQUIRED
03/05/2021
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/17/2021
ES7R
TEAS SECTION 7 REQUEST RECEIVED
01/22/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
12/15/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/29/2020
PUBO
PUBLISHED FOR OPPOSITION
09/29/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/09/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/25/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
08/25/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/25/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
08/25/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/25/2020
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
08/21/2020
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
08/18/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/05/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
08/05/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/05/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
08/05/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/05/2020
DOCK
ASSIGNED TO EXAMINER
08/03/2020
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
05/20/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/19/2020
NWAP
NEW APPLICATION ENTERED
05/11/2020
Continuous trademark protection
Get notified about every new filing that threatens 9 ML STERILE OPHTHALMIC DROPS PILOCARPINE HCI / PHENYLEPHRINE HCI / PHENIRAMINE / KETOROLAC 0.302% / 0.624% / 0.0772% / 0.01% EYEFOCUS BY OSRX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.